Expanding the Definition of Value to Encompass Whole Health Through Standardized Patient-Centered Outcomes Measurement for Obesity

Speaker(s)

Moderator: Spencer Connell, DAT, ICHOM, Indianapolis, IN, USA
Panelists: Laura Pizzi, PharmD, MPH, Chief Science Officer, ISPOR, Lawrence Township, NJ, USA; Christopher Blanchette, PhD, MBA, Novo Nordisk, Plainsboro, NJ, USA; Morgan Salmon, ., AHP-Obesidad, Copenhagen, Denmark

ISSUE:

The global prevalence of obesity has nearly tripled over the past decades, reaching epidemic proportions, making its effective clinical management a global priority. Despite substantial research, the complex and relapsing nature of obesity, driven by various clinical, socioeconomic, genetic, and environmental factors, continues to hinder progressUtilizing a holistic view of health is essential for HEOR analyses of obesity, requiring expanded definitions of healthcare value.This issue panel will explore how ICHOM's standardized outcome measures for obesity aligns with ISPOR’s Strategic Plan 2030, and from a practical standpoint, how the measurement set can be applied to HEOR analyses and obesity policy. Our panelists, including a clinician, researchers, and patient, will discuss research implications, patient perspectives, and policy impacts of these measures, providing a comprehensive overview of their potential to improve obesity management.

OVERVIEW:

The session will begin with an overview provided by Jennifer Bright, who will cover the unique aspects of ICHOM’s development of standardized outcome sets for obesity, their global track record of use, and the key debate topics. Despite the high global prevalence and huge healthcare burden of obesity, its effective clinical management remains a challenge. ICHOM’s standardized patient-centered outcome measure may offer a promising solution to address this challenge.

The session will include:

  • Introduction (10 minutes): Ms. Bright on ICHOM’s obesity set development.
  • Panelist Presentations (7 minutes each):
  • Dr. Patton: Standardised outcome measurement implications for direct patient care, research, and advocacy
  • Dr. Pizzi: Linkage between obesity and whole health which is a strategic priority for ISPOR and by extension HEOR professionals
  • Dr. Blanchette: applied experience in HEOR analyses of obesity drugs (GLP-1 inhibitors) and utility of the ICHOM measurement set for this work
  • Moderated Debate (20 minutes): Discussion on overcoming challenges and optimizing outcomes/care.
  • Interactive Q&A (9 minutes)

Code

250

Topic

Patient-Centered Research